A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention

Exclusion Criteria

• •Patients diagnosed with basilar, ophthalmoplegic or hemiplegic migraine as shown in the current/past medical history.
• •Patients having an experience of non-migraine headaches on more than 6 days per 4 weeks in the past 6 months prior to study start
• •Patients receiving regular treatment during the four (4) weeks preceding the Baseline with psychoactive drugs (e.g. hypnotics, benzodiazepines, neuroleptics) except antidepressants (eg. SSRIs, SNRIs, Tri- or Tetracyclics).
• •Patients receiving migraine prevention medications during past three (3) months preceding Baseline
• •Patients receiving topiramate as migraine prevention medication during past six (6) months preceding Baseline
• •Patients receiving metamizole as acute treatment of migraine during past three (3) months preceding Baseline
• •Patients using (or having used within four (4) weeks before the treatment start) drug treatments that are potent inhibitors of OATP transporters (e.g. rifampin).
• •Any psychiatric condition (e.g., schizophrenia, dementia, bipolar disorder) as shown in the past medical history prior to study start
• •Patients with recent (within the last three \[3\] years prior to study start) and/or recurrent history of autonomic dysfunction (e.g. recurrent episodes of fainting, palpitations, orthostatic hypotension etc.).
• •Pregnant or nursing (lactating) women. Baselines (1 and 2).